Nucleotide News and Research

RSS

Pharmasset announces data from PSI-352938 single ascending dose study

Pharmasset, Inc. announced today that safety and pharmacokinetic data from the PSI-352938 single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.

28 Jul 2010

Scientists identify genetic variants for breast cancer

Women with higher risk scores that consisted of having certain genetic variants most strongly linked to breast cancer had an associated higher risk of breast cancer, with these scores also highly predictive of estrogen receptor-positive disease, according to a study in the July 28 issue of JAMA.

28 Jul 2010

Idenix second-quarter total revenues decrease to $1.3 million

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million.

27 Jul 2010

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.

22 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Susceptibility to Behcet's disease associated with genes involved in body's immune response

Researchers with the National Institutes of Health have found susceptibility to Behcet's disease, a painful, inflammatory condition, to be associated with genes involved in the body's immune response.

14 Jul 2010

GWAS suggests genetic variant with increased oncogene expression for cancer study

The study, published July 13th in Genome Research, showcases a new protocol for studying the activity of cancer-risk variants suggested by GWAS studies. The results also underscore the dramatic consequences of small genetic changes even in the vast stretches of DNA, known as "gene deserts," that do not code for proteins.

13 Jul 2010

Researchers identify genetic variant associated with increased risk of AAA

Geisinger researchers are part of an international team that has identified a genetic variant more common in individuals with abdominal aortic aneurysms. This is one of the largest studies ever into the genetics of AAA. The results of the work will appear in this week's online edition of Nature Genetics.

13 Jul 2010

Researchers explore range of potential new fuel sources in nature

On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.

12 Jul 2010

Mutations in Siglec-8 gene may play role in asthma: Research

A gene that encodes a protein responsible for determining whether certain immune cells live or die shows subtle differences in some people with asthma, a team led by Johns Hopkins researchers reports in the June European Journal of Human Genetics.

1 Jul 2010

An innovative genetic prediction algorithm

A University of Toledo doctoral candidate in biomedical sciences recently combined the inspiration he received from his grandfather, values learned from his mother, insights gleaned from his mentors and processing power tapped from a supercomputer to unlock a few of the many secrets of the human genome.

29 Jun 2010

People with certain chitinase gene variants at increased risk of severe asthma attacks

Exposure to high levels of fungus may increase the risk of severe asthma attacks among people with certain chitinase gene variants, according to a study from Harvard Medical School, Harvard Pilgrim Health Care Institute and Brigham and Women's Hospital.

24 Jun 2010

ABL to host CRP-Santé COMET subtyping tool within TherapyEdge servers

The licensing and distribution agreement allows ABL to directly host COMET (COntext-based Modeling for Expeditious Typing) subtyping tool developed at CRP-Santé within the TherapyEdge servers; it will mainly interact with the ViroScore Suite system to characterize HIV-1 virus subtypes.

24 Jun 2010

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the "John et al." patent (Application No. 10/384,463), which covers methods of inhibiting mutant genes with double-stranded RNAs from 19 to 30 nucleotides in length.

18 Jun 2010

3 new genes in genetic research of suicidal behaviour

Three genes that have barely been studied to date have now provided fresh knowledge about patients with suicidal backgrounds. This is the result of a study by a team of Spanish researchers at Mount Sinai Hospital and Columbia University in the City of New York (United States), which found that several mutations are involved. This finding could help to develop future genetic tests to identify predisposition to suicide, without ignoring the importance of social and cultural factors.

16 Jun 2010

CNVs increases patients' susceptibility to severe sepsis

Genetic makeup has been identified as a key factor leading to the development of sepsis, a systemic inflammatory reaction that occurs during infection. Sepsis is considered severe when associated with organ dysfunction.

14 Jun 2010

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

A small genetic change can predict how people infected with hepatitis C react to treatment, paving the way to personalised therapy for this difficult to treat disease, the annual conference of the European Society of Human Genetics will hear today (Sunday 13 June). Dr. Zoltan Kutalik, from the Department of Medical Genetics, University of Lausanne, Switzerland, will tell delegates that individuals with this change, in a gene encoding for the antiviral cytokine (cell-signalling molecule) interferon lamda, reacts less well to treatment.

14 Jun 2010

New study to use genetic 'chips' for examining DNA from over 20,000 heart disease patients

New research at the University of Leicester will use the latest genetic techniques to examine DNA from over 20,000 patients with heart disease.

11 Jun 2010

Idenix initiates IDX320 proof-of-concept study for HCV infection

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.

10 Jun 2010

Nucleotide News and Research

Pharmasset announces data from PSI-352938 single ascending dose study

Scientists identify genetic variants for breast cancer

Idenix second-quarter total revenues decrease to $1.3 million

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Susceptibility to Behcet's disease associated with genes involved in body's immune response

GWAS suggests genetic variant with increased oncogene expression for cancer study

Researchers identify genetic variant associated with increased risk of AAA

Researchers explore range of potential new fuel sources in nature

Mutations in Siglec-8 gene may play role in asthma: Research

An innovative genetic prediction algorithm

People with certain chitinase gene variants at increased risk of severe asthma attacks

ABL to host CRP-Santé COMET subtyping tool within TherapyEdge servers

Risk, incidence of VTE differs between races

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

3 new genes in genetic research of suicidal behaviour

CNVs increases patients' susceptibility to severe sepsis

Genetic variation can predict how people infected with hepatitis C react to treatment: Scientists

New study to use genetic 'chips' for examining DNA from over 20,000 heart disease patients

Idenix initiates IDX320 proof-of-concept study for HCV infection

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News